May 14, 2018 / 8:13 PM / 3 months ago

BRIEF-Pfenex Announces Top-Line PF708 Study Results In Osteoporosis Patients

May 14 (Reuters) - Pfenex Inc:

* PFENEX ANNOUNCES POSITIVE TOP-LINE PF708 STUDY RESULTS IN OSTEOPOROSIS PATIENTS, ON-TRACK FOR SUBMISSION OF NEW DRUG APPLICATION IN THIRD QUARTER 2018

* PFENEX INC - ON-TRACK FOR SUBMISSION TO FDA IN Q3 2018, WITH A POTENTIAL COMMERCIAL LAUNCH IN UNITED STATES AS EARLY AS Q3 2019

* PFENEX INC - NO IMBALANCES IN SEVERITY OR INCIDENCE OF ADVERSE EVENTS FROM PF708 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below